Mepicart (Mepivacaine Hydrochloride)

Mepicart is used as a local anesthetic to achieve temporary loss of sensation in targeted tissues.

• Infiltration anesthesia: provides localized numbness for minor surgical or diagnostic procedures.
• Peripheral nerve block: enables regional anesthesia for limb surgeries or pain management.
• Dental procedures: facilitates pain‑free tooth extractions, restorations and other oral surgeries.

• Mepivacaine hydrochloride acts by reversibly binding to voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel and preventing the influx of sodium ions. This inhibition blocks the generation and propagation of action potentials, resulting in a temporary loss of sensory and motor nerve conduction in the administered area.

Adverse reactions to Mepicart are generally related to its pharmacologic class and route of administration.

Common Side Effects

• Transient tingling or numbness at the injection site.
• Mild swelling or erythema around the administered area.
• Temporary dizziness or light‑headedness.
• Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Allergic reactions such as urticaria, bronchospasm or anaphylaxis.
• Cardiovascular disturbances including hypotension, bradycardia or arrhythmias.
• Central nervous system toxicity presenting as seizures or loss of consciousness.
• Persistent paresthesia or prolonged motor block beyond expected duration.

When using Mepicart, clinicians should observe specific safety measures to minimize risks.

• Patient assessment: evaluate medical history for cardiac, hepatic or renal disease before administration.
• Dose limitation: avoid exceeding recommended maximum dose for the specific procedure.
• Monitoring: observe vital signs and neurological status during and after injection.
• Contraindications: do not use in patients with known hypersensitivity to amide‑type local anesthetics.
• Drug interactions: review concomitant medications that may potentiate cardiac or CNS effects.
• Store below 25°C: keep in original container, protect from light and moisture.

Mepicart may interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid)

• Class I antiarrhythmic drugs (e.g., quinidine, procainamide): may exacerbate cardiotoxicity.
• Monoamine oxidase inhibitors (MAOIs): increase risk of severe hypertension when combined with vasoconstrictors.
• High‑dose beta‑adrenergic antagonists: can potentiate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

• Other local anesthetics: cumulative toxicity risk if combined.
• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation or respiratory depression.
• Diuretics: may alter plasma protein binding, affecting drug levels.